| Saver, Jeffrey |
| Recruiting | 2/3 | 544 | RoW | rhTNK-tPA, TNKase, TNK-tPA, Endovascular treatment, intra-arterial treatment, interventional therapy | Xinqiao Hospital of Chongqing, CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD | Stroke, Acute, Stroke, Ischemic | 12/25 | 03/26 | | |
| Recruiting | 2b | 90 | US | Tight control of end-tidal CO2 levels | University of California, Los Angeles, University of Southern California | Acute Stroke | 01/25 | 01/25 | | |
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY) |
|
|
| Completed | N/A | 100 | US | BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group | BrainQ Technologies Ltd. | Ischemic Stroke | 11/23 | 01/24 | | |
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment |
|
|
| Recruiting | N/A | 122 | US | Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions | BrainQ Technologies Ltd. | Ischemic Stroke | 07/26 | 10/26 | | |
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability |
|
|
| Recruiting | N/A | 1060 | US | Endovascular Stroke Treatment, Medical Management | University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai | Stroke, Stroke, Acute, Stroke, Ischemic | 01/28 | 04/28 | | |
| Cooper, Christopher J |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
NCT05232253: Cystoealstometer (Bladder Monitor Device)-Home Use |
|
|
| Active, not recruiting | N/A | 30 | US | Cystoelastometer - Urodynamics Testing | University of Iowa | Urinary Bladder, Neurogenic | 02/26 | 02/27 | | |
NCT04128709: Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use |
|
|
| Recruiting | N/A | 50 | US | Urodynamics Testing | Christopher Cooper | Urinary Bladder, Neurogenic | 12/25 | 12/25 | | |
| Klausner, Jeffrey D |
| Recruiting | 3 | 400 | US | Cefixime 400mg, supprax, benzathine penicillin, bicillin | University of Southern California, AIDS Healthcare Foundation, Universidad Peruana Cayetano Heredia | Syphilis, Human Immunodeficiency Virus | 01/25 | 06/25 | | |
| Recruiting | 2 | 24 | US | Group B, Linezolid 10d, zyvox, Group A, Penicillin, bicillin | University of Southern California, Universidad Peruana Cayetano Heredia, The University of Texas Health Science Center, Houston | Syphilis | 03/25 | 03/25 | | |
NCT04446611: Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes |
|
|
| Recruiting | N/A | 2500 | RoW | First antenatal care + test-of-cure, First antenatal care + week 30-34 gestation (no test-of-cure) | Foundation for Professional Development (Pty) Ltd, University of Southern California, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), University of Cape Town, University of Alabama at Birmingham, Louisiana State University Health Sciences Center in New Orleans | Sexually Transmitted Infection, HIV/AIDS, Cost-effectiveness, Birth Outcomes, Vaginal Microbiome, Neisseria Gonorrhoeae, Chlamydia Trachomatis, Trichomonas Vaginalis, Antenatal Care, Pregnancy | 12/24 | 04/25 | | |
| Rettig, Matthew B |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 2 | 14 | US | Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation | Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer | 01/24 | 01/25 | | |
CHOMP, NCT04104893: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
|
|
| Recruiting | 2 | 30 | US | Pembrolizumab, Keytruda | VA Office of Research and Development, Merck Sharp & Dohme LLC | Metastatic Castration Resistant Prostate Cancer | 03/25 | 12/25 | | |
| Recruiting | 2 | 100 | US | Carboplatin, Paraplatin, Olaparib, Lynparza | VA Office of Research and Development | Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations | 08/25 | 08/25 | | |
SNARE, NCT05593497: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss |
|
|
| Recruiting | 2 | 30 | US | Capivasertib, abiraterone acetate | VA Office of Research and Development | High-Risk Prostate Cancer | 05/27 | 08/27 | | |
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects |
|
|
| Active, not recruiting | 2 | 70 | US | Olaparib, Lynparza, Abiraterone Acetate, Prednisone | Northwestern University, AstraZeneca, National Cancer Institute (NCI) | Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer | 12/26 | 01/27 | | |
NCT06084338: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc |
|
|
| Recruiting | 2 | 60 | US | stereotactic ablative radiotherapy, SBRT, Pluvicto, Lu177-PSMA, topical testosterone, androgel | VA Office of Research and Development | Prostate Cancer | 11/27 | 12/28 | | |
| Recruiting | 1/2 | 30 | US | INKmune | Inmune Bio, Inc. | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 05/25 | 11/25 | | |
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib |
|
|
| No Longer Available | N/A | | NA | Trametinib 2 mg | Jonsson Comprehensive Cancer Center, Novartis | Progressive Metastatic Castrate Resistant Prostate Cancer | | | | |
NCT05435495: Mechanisms of Resistance to PSMA Radioligand Therapy |
|
|
| Recruiting | N/A | 125 | US | Single-photon emission computed tomography, SPECT/CT, Blood Draw, Tumor Biopsy, Biopsy | University of California, San Francisco, National Cancer Institute (NCI), Prostate Cancer Foundation | Prostate Cancer | 12/24 | 12/24 | | |
NCT06682390: Role of Race in Nutritional Approach in Men on ADT |
|
|
| Recruiting | N/A | 70 | US | Hypocaloric anti-inflammatory diet | University of California, Los Angeles, National Comprehensive Cancer Network | Prostate Cancer Metastatic Disease | 11/25 | 11/25 | | |
| Tashkin, Donald P |
| Recruiting | 2 | 21 | US | Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide | University of California, Los Angeles, Theravance Biopharma, Mylan Pharmaceuticals Inc | COPD, Acute Respiratory Failure | 04/25 | 06/25 | | |
| Liebeskind, David S |
| Recruiting | 3 | 182 | US | Head of Bed Positioning | University of Tennessee Health Science Center, National Institute of Nursing Research (NINR) | Ischemic Stroke | 06/22 | 06/23 | | |
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics |
|
|
| Active, not recruiting | 3 | 385 | Canada, US | Revascularization, Intensive Medical Management (IMM) alone | Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles | Internal Carotid Artery Stenosis, Cognitive Impairment | 01/27 | 07/27 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
NCT05518305: Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis |
|
|
| Recruiting | N/A | 250 | US | Medical Imaging | University of California, Los Angeles, University of Pittsburgh Medical Center, University of Chicago, Bay State Clinical Trials, Inc., Yale University, University of Vermont | Stroke, TIA, Ischemic Stroke, Ischemic | 09/27 | 09/27 | | |
CAPTIVA-MRI, NCT05907629: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging |
|
|
| Recruiting | N/A | 300 | US | MRI | Yale University, National Institute of Neurological Disorders and Stroke (NINDS) | Stroke, Intracranial Atherosclerotic Stenosis (ICAS) | 03/29 | 03/29 | | |
| Gonzalez, Nestor R |
| Enrolling by invitation | N/A | 300 | NA | According to current clinical care standards | Cedars-Sinai Medical Center | Stroke, Transient Ischemic Attack, Atherosclerosis, Intracranial Arterial Stenosis, Moyamoya | 07/30 | 12/30 | | |
NCT02910180: Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders |
|
|
| Recruiting | N/A | 900 | US | | Cedars-Sinai Medical Center | Cerebrovascular Diseases, Ischemic Stroke, Repository | 12/30 | 12/30 | | |
| McMahon, Maureen |
| Terminated | 3 | 275 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Lupus Nephritis | 09/23 | 09/23 | | |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 03/27 | 07/30 | | |
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders |
|
|
| Completed | 2 | 257 | US | Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent | National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc. | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS) | 06/23 | 03/24 | | |
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus |
|
|
| Terminated | 2 | 9 | US | Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin | National Institute of Allergy and Infectious Diseases (NIAID) | Systemic Lupus Erythematosus | 04/24 | 04/24 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
| Coordinator |
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) |
|
|
| Recruiting | 4 | 12 | US | Asceniv™ | ADMA Biologics, Inc. | Primary Immune Deficiency | 03/23 | 06/23 | | |
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies |
|
|
| Recruiting | 3 | 143 | Europe, US | Intervention/Treatment | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/25 | 03/26 | | |
| Recruiting | 3 | 690 | US | Brilaroxazine, RP5063, Placebo | Reviva Pharmaceuticals | Schizophrenia | 02/25 | 02/25 | | |
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 212 | US | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 05/25 | 01/26 | | |
REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 84 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 03/26 | 11/26 | | |
REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 126 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 04/26 | 12/26 | | |
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 3 | 188 | Europe, US, RoW | Veligrotug (VRDN-001), Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease |
|
|
| Recruiting | 2 | 100 | US | Carmustine 7.7Mg Wafer, GLIADEL | University of Nebraska, Arbor Pharmaceuticals, Inc. | Brain Tumor - Metastatic | 12/25 | 12/26 | | |
NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors |
|
|
| Recruiting | 2 | 200 | RoW | YL202 should be intravenously infused | MediLink Therapeutics (Suzhou) Co., Ltd. | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 11/26 | 11/28 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 640 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/27 | | |
| Recruiting | N/A | 2000 | US | | Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health (NIH), University of Chicago, University of Alabama at Birmingham, Rush University, Washington University School of Medicine, Medical University of South Carolina, University Hospitals Cleveland Medical Center, Louisiana State University Health Sciences Center Shreveport, University of Florida, University of Maryland, The University of Texas Health Science Center, Houston, Ochsner Health System | Parkinson Disease | 12/26 | 12/26 | | |
NCT06186596: Self-Administered Intralesional Injections for Acne |
|
|
| Recruiting | N/A | 150 | US | Triamcinolone delivered via injection assistance device | ACOM Labs | Acne Vulgaris | 01/24 | 01/24 | | |
NCT05879198: Train Your Brain: A Pilot Project to Improve Memory and Decision Making |
|
|
| Completed | N/A | 24 | US | Computer-based Intervention | Henry Ford Health System, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Behavior, Health | 09/23 | 09/23 | | |
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD |
|
|
| Recruiting | N/A | 1410 | US | | Aqtual, Inc. | Rheumatoid Arthritis | 06/25 | 12/25 | | |
NCT04642898: Increasing Treatment Efficacy Using SMART Methods for Personalizing Care |
|
|
| Completed | N/A | 66 | US | Standard UP Treatment, Capitalization UP Treatment, Compensation UP Treatment | Shannon E. Sauer-Zavala, National Institute of Mental Health (NIMH) | Anxiety Disorders, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder | 06/24 | 06/24 | | |
NCT03594994: Metabolic Effects of Sleep Extension in People With Obesity |
|
|
| Completed | N/A | 40 | US | Sleep extension | Washington University School of Medicine | Insulin Resistance, Obesity | 07/24 | 07/24 | | |
NCT06242704: Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth |
|
|
| Recruiting | N/A | 72 | US | Working Memory Training, Working Memory | Henry Ford Health System | Behavior, Health | 08/26 | 08/26 | | |
NCT04587518: Five Factor Model Treatment for Borderline Personality Disorder |
|
|
| Completed | N/A | 100 | US | Personality-Based Cognitive Behavioral Therapy | Shannon E. Sauer-Zavala | Borderline Personality Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
ELEVATE-HF, NCT06592508: Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 180 | US | Remote Virtual Cardiology Program | Duke University, Ventricle Health | Heart Failure; With Decompensation | 08/26 | 08/26 | | |
NCT03701828: Liver Health and Metabolic Function in People With Obesity |
|
|
| Enrolling by invitation | N/A | 30 | US | Weight loss surgery, Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion | Washington University School of Medicine | Non-Alcoholic Fatty Liver Disease | 11/24 | 03/25 | | |
| Recruiting | N/A | 87 | US | Telemedicine | University of Pennsylvania | Psoriatic Arthritis | 02/25 | 02/25 | | |
| Recruiting | N/A | 200 | Europe | Modified prolonged exposure, Brief intervention, cognitive behavioral therapy | St. Olavs Hospital, Norwegian University of Science and Technology, The Research Council of Norway, Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening), National Centre for Emergency Primary Health Care, NORCE, UiT The Arctic University of Norway | Post Traumatic Stress Disorder, Rape Sexual Assault, Sexual Dysfunctions, Psychological, Pelvic Floor Myalgia, Pelvic Pain Syndrome, Depression, Anxiety, Sleep Disturbance, Activity, Motor, Cortisol Deficiency | 05/25 | 12/27 | | |
| Recruiting | N/A | 506 | US | CHOICES, eBook | University of Florida, National Human Genome Research Institute (NHGRI) | Sickle Cell Disease, Sickle Cell Trait | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 220 | US | EXTEND Plus, EXTEND | Duke University, National Institute of Nursing Research (NINR) | Diabetes Mellitus, Type 2, Hypertension | 10/25 | 10/25 | | |
| Wang, Tisha |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 11/23 | 11/24 | | |
| Bevis, Danielle |
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
|
|
| Recruiting | 3 | 399 | Europe, Canada, US, RoW | Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib | Swedish Orphan Biovitrum, PSI CRO | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 12/26 | 07/27 | | |
|
| Wilson, Rujuta B |
| Recruiting | N/A | 40 | US | Dance, expressive movement | University of California, Los Angeles, Health Resources and Services Administration (HRSA) | Neurodevelopmental Disorders | 03/24 | 03/24 | | |
